The therapeutic effect of Nesfatin-1 on acute myocardial ischemia/reperfusion injury; a systematic review and meta-analysis
Iranian Journal of Emergency Medicine,
Vol. 10 No. 1 (2023),
30 November 2022
In recent years, various peptides have been introduced for the complementary treatment and management of post-reperfusion injuries. Nesfatin-1, a peptide secreted by the nervous system and peripheral tissues, modulates cardiac function, and plays an important role in the cardiovascular response to stress conditions. This systematic review and meta-analysis aims to investigate the preclinical evidence on the effect of Nesfatin-1 administration in the improvement of cardiac ischemia/reperfusion injury.
Online databases of PubMed, Embase, Web of Science, and Scopus were searched until November 2nd, 2022, for articles investigating the therapeutic effects of Nesfatin-1 administration on myocardial ischemia/reperfusion injury in preclinical models. Cardiac functions, infarct size, myocardial tissue fibrosis, inflammation, oxidative stress, apoptosis, necroptosis, and necrosis were chosen as outcomes. The results are reported as an overall standardized mean difference (SMD) and 95% confidence interval (CI).
Our results demonstrate that the administration of Nesfatin-1 improves cardiac parameters such as ejection fraction (SMD = 3.94, 95% CI: 0.30 to 7.58), heart rate (SMD = 3.30, 95% CI: 0.41 to 6.18), and negative dp/dt (SMD = 2.05, 95% CI: 0.60 to 3.50) and positive dp/dt (SMD = 2.78, 95% CI: 0.56 to 4.99). Nesfatin-1 was shown to significantly reduce myocardial infarct size (SMD = -4.32, 95% CI: -5.95 to -2.69 and fibrosis (SMD = -3.91, 95% CI: -5.67 to -2.15). Apoptotic score (SMD = -2.07, 95% CI: -3.51 to -0.63) and oxidative stress were also reduced subsequent to Nesfatin-1 administration. Nesfatin-1 was not shown to decrease inflammation, necroptosis, and necrosis.
In conclusion, we demonstrated that Nesfatin-1 could serve as a potential therapeutic agent in ameliorating the secondary damages during myocardial I/R injury. Nesfatin-1 administration can preserve cardiac function by reducing oxidative stress, apoptosis, and myocardial necrosis. However, much more studies are required to endorse further clinical translation of Nesfatin-1 to be utilized in the management of myocardial I/R injury.
- Ischemia/reperfusion injury
- Myocardial reperfusion injury
How to Cite
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. Journal of the American College of Cardiology. 2020;76(25):2982-3021.
Crowhurst J. Contemporary angiography in the diagnosis and treatment of cardiovascular disease. 2020.
Sánchez-Hernández CD, Torres-Alarcón LA, González-Cortés A, Peón AN. Ischemia/Reperfusion Injury: Pathophysiology, Current Clinical Management, and Potential Preventive Approaches. Mediators of Inflammation. 2020;2020.
Wu M-y, Yiang G-t, Liao W-T, Tsai AP-Y, Cheng Y-L, Cheng P-W, et al. Current mechanistic concepts in ischemia and reperfusion injury. Cellular Physiology and Biochemistry. 2018;46(4):1650-67.
Moens A, Claeys M, Timmermans J, Vrints C. Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. International journal of cardiology. 2005;100(2):179-90.
Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. New England Journal of Medicine. 2007;357(11):1121-35.
Fernandez Rico C, Konate K, Josse E, Nargeot J, Barrère-Lemaire S, Boisguérin PJFiCM. Therapeutic peptides to treat myocardial ischemia-reperfusion injury. 2022;9:64.
Ayada C, Toru Ü, Korkut Y. Nesfatin-1 and its effects on different systems. Hippokratia. 2015;19(1):4-10.
Angelone T, Filice E, Pasqua T, Amodio N, Galluccio M, Montesanti G, et al. Nesfatin-1 as a novel cardiac peptide: identification, functional characterization, and protection against ischemia/reperfusion injury. Cellular and Molecular Life Sciences. 2013;70(3):495-509.
Sharifi M, Nazarinia D, Ramezani F, Azizi Y, Naderi N, Aboutaleb N. Necroptosis and RhoA/ROCK pathways: molecular targets of Nesfatin-1 in cardioprotection against myocardial ischemia/reperfusion injury in a rat model. Molecular Biology Reports. 2021;48(3):2507-18.
Naseroleslami M, Sharifi M, Rakhshan K, Mokhtari B, Aboutaleb N. Nesfatin-1 attenuates injury in a rat model of myocardial infarction by targeting autophagy, inflammation, and apoptosis. Archives of physiology and biochemistry. 2023;129(1):122-30.
Su RY, Geng XY, Yang Y, Yin HS. Nesfatin-1 inhibits myocardial ischaemia/reperfusion injury through activating Akt/ERK pathway-dependent attenuation of endoplasmic reticulum stress. Journal of cellular and molecular medicine. 2021;25(11):5050-9.
Sharifi M, Nazarinia D, Ramezani F, Azizi Y, Naderi N, Aboutaleb N. Necroptosis and RhoA/ROCK pathways: molecular targets of Nesfatin-1 in cardioprotection against myocardial ischemia/reperfusion injury in a rat model. Mol Biol Rep. 2021;48(3):2507-18.
Tasatargil A, Kuscu N, Dalaklioglu S, Adiguzel D, Celik-Ozenci C, Ozdem S, et al. Cardioprotective effect of nesfatin-1 against isoproterenol-induced myocardial infarction in rats: Role of the Akt/GSK-3β pathway. Peptides. 2017;95:1-9.
Tawfik M, Abd Al-Aleem D, Ibrahim R, Abaza R. Effect of nesfatin-1 on ischaemia-reperfusion injury in isolated heart of albino rats. Zagazig Uni Med J. 2016;22(6):1-11.
Shi Z, Fu F, Yu L, Xing W, Su F, Liang X, et al. Vasonatrin peptide attenuates myocardial ischemia-reperfusion injury in diabetic rats and underlying mechanisms. Am J Physiol Heart Circ Physiol. 2015;308(4):H281-90.
Huynh DN, Elimam H, Bessi VL, Ménard L, Burelle Y, Granata R, et al. A Linear Fragment of Unacylated Ghrelin (UAG(6-13)) Protects Against Myocardial Ischemia/Reperfusion Injury in Mice in a Growth Hormone Secretagogue Receptor-Independent Manner. Front Endocrinol (Lausanne). 2018;9:798.
Li KP, Zhang HY, Xu XD, Ming Y, Li TJ, Song ST. Recombinant Human Brain Natriuretic Peptide Attenuates Myocardial Ischemia-Reperfusion Injury by Inhibiting CD4(+) T Cell Proliferation via PI3K/AKT/mTOR Pathway Activation. Cardiovasc Ther. 2020;2020:1389312.
Oh IS, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443(7112):709-12.
Angelone T, Rocca C, Pasqua T. Nesfatin-1 in cardiovascular orchestration: From bench to bedside. Pharmacol Res. 2020;156:104766.
Dai H, Li X, He T, Wang Y, Wang Z, Wang S, et al. Decreased plasma nesfatin-1 levels in patients with acute myocardial infarction. Peptides. 2013;46:167-71.
Honda HM, Korge P, Weiss JN. Mitochondria and ischemia/reperfusion injury. Ann N Y Acad Sci. 2005;1047:248-58.
Chen CL, Zhang L, Jin Z, Kasumov T, Chen YR. Mitochondrial redox regulation and myocardial ischemia-reperfusion injury. Am J Physiol Cell Physiol. 2022;322(1):C12-c23.
Erfani S, Moghimi A, Aboutaleb N, Khaksari M. Nesfatin-1 Improve Spatial Memory Impairment Following Transient Global Cerebral Ischemia/Reperfusion via Inhibiting Microglial and Caspase-3 Activation. J Mol Neurosci. 2018;65(3):377-84.
Ruan Y, Zeng J, Jin Q, Chu M, Ji K, Wang Z, et al. Endoplasmic reticulum stress serves an important role in cardiac ischemia/reperfusion injury (Review). Exp Ther Med. 2020;20(6):268.
Ayada C, Toru Ü, Genç O, Akcılar R, Şahin S. Balanced oxidative status by nesfatin-1 in intestinal ischemia-reperfusion. Int J Clin Exp Med. 2015;8(3):3318-24.
Jiang G, Wang M, Wang L, Chen H, Chen Z, Guo J, et al. The protective effect of nesfatin-1 against renal ischemia-reperfusion injury in rats. Ren Fail. 2015;37(5):882-9.
Diwan A, Tran T, Misra A, Mann DL. Inflammatory mediators and the failing heart: a translational approach. Curr Mol Med. 2003;3(2):161-82.
Tang CH, Fu XJ, Xu XL, Wei XJ, Pan HS. The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain. Peptides. 2012;36(1):39-45.
Karadeniz Cerit K, Koyuncuoğlu T, Yağmur D, Peker Eyüboğlu İ, Şirvancı S, Akkiprik M, et al. Nesfatin-1 ameliorates oxidative bowel injury in rats with necrotizing enterocolitis: The role of the microbiota composition and claudin-3 expression. J Pediatr Surg. 2020;55(12):2797-810.
Kolgazi M, Ozdemir-Kumral ZN, Cantali-Ozturk C, Demirci EK, Yuksel M, Sirvanci S, et al. Anti-inflammatory effects of nesfatin-1 on acetic acid-induced gastric ulcer in rats: involvement of cyclo-oxygenase pathway. J Physiol Pharmacol. 2017;68(5):765-77.
Cohn JN. Neuroendocrine activation after acute myocardial infarction. Am J Cardiol. 1990;65(19):28i-31i.
Yosten GL, Samson WK. Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol. 2009;297(2):R330-6.
- Abstract Viewed: 72 times
- pdf Downloaded: 61 times